Document Detail


Hemolysis and cell-free hemoglobin drive an intrinsic mechanism for human disease.
MedLine Citation:
PMID:  22446184     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Blood transfusion represents the first and most prescribed cell-based therapy; however, clinical safety and efficacy trials are lacking. Clinical cohort studies have suggested that massive transfusion and/or transfusion of aged stored blood may contribute to multiorgan dysfunction in susceptible patients. In this issue of the JCI, Baek and colleagues report that aged stored blood hemolyzes after massive transfusion in a guinea pig model. Hemolysis led to vascular and kidney injury that was mediated by cell-free plasma hemoglobin and prevented by coinfusion of the specific hemoglobin scavenger protein, haptoglobin. These studies support an expanding body of research indicating that intravascular hemolysis is a pathological mechanism in several human diseases, including multiorgan dysfunction after either massive red blood cell transfusion or hemoglobin-based blood substitute therapy, the hemoglobinopathies, malaria, and other acquired and genetic hemolytic conditions.
Authors:
Mark T Gladwin; Tamir Kanias; Daniel B Kim-Shapiro
Related Documents :
8735324 - Leukocyte-reduced blood components: patient benefits and practical applications.
1625104 - The insufficiency of single point diffusive air flow integrity testing.
6721804 - Measurement of tetracycline levels in parakeets.
3286574 - Local intravascular effects of the nitinol wire blood clot filter.
6661164 - Relationship between regional myocardial blood flow and mitochondrial function.
9609894 - Doppler sonography of the portal vein and hepatic artery: measurement of a prandial eff...
Publication Detail:
Type:  Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-03-26
Journal Detail:
Title:  The Journal of clinical investigation     Volume:  122     ISSN:  1558-8238     ISO Abbreviation:  J. Clin. Invest.     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-04-02     Completed Date:  2012-07-06     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  7802877     Medline TA:  J Clin Invest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1205-8     Citation Subset:  AIM; IM    
Affiliation:
Vascular Medicine Institute and Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA. gladwinmt@upmc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Blood Preservation*
Blood Transfusion / adverse effects*
Haptoglobins / therapeutic use*
Hemoglobins / adverse effects*
Hemolysis*
Humans
Kidney / pathology*
Male
Grant Support
ID/Acronym/Agency:
P01HL103455/HL/NHLBI NIH HHS; R01HL096973/HL/NHLBI NIH HHS; R01HL098032/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Haptoglobins; 0/Hemoglobins
Comments/Corrections
Comment On:
J Clin Invest. 2012 Apr 2;122(4):1444-58   [PMID:  22446185 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chk'ing p53-deficient breast cancers.
Next Document:  Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion tha...